Cuevas BJF, Sánchez HG, Espinoza SR

Language: Spanish
References: 15
Page: 11-16
PDF size: 372.55 Kb.

ABSTRACT

Background: The precise definition of white coat hypertension (WCH) has been an issue for discussion and debate; it is defined as the systolic blood pressure over 140mm Hg or diastolic blood pressure over or equal to 90 mm Hg measured on a patient who is in a hospital or medical office, and blood pressure at home must be under 135/85 mm Hg.
Material and Method: Nursery employees from Ticoman General Hospital identificated patients with a high tensional number . The inclusion criteria were: eighteen-to-eighty-year-old patients without previous arterial hypertension diagnosis. And the non-inclusion criteria were: diabetes mellitus type 1 or type 2, renal insufficiency, pregnancy, hyperthyroidism, cardiopathies or the usage of medicines that modify the blood pressure, patients under painful or stressful procedures, and/or their refusal to be part of the study. Association will be determined with the OR.
Results: 49 starting hypertension patients were included, from which 27 (55%) arterial systemic hypertension patients were confirmed, and 22 (45%) white coat hypertension patients as well. The association of BMI›30 with the presence of white coat hypertension, determined through the OR was OR=4.53 (IC95% 1.34-15.37; p=0.01; and the association with high abdominal circumference was OR=0.77 (IC95% 0.23-2.52; p: 0.45).
Conclusion:Obesity may be a risk factor for the WCH, whose prevalence in our hospital environment was 45%.

REFERENCES

1. Mehmet Rami Helvaci, et al. What a high prevalence of white coat hypertension in society. Internal Medicine 2006;45:670-674.

2. Landray MJ, Lip GYH. White coat hypertension: a recognized syndrome with uncertain implications. Journal of Human Hypertension 1999;13:5-8.

3. White WB. Ambulatory blood-pressure monitoring in clinical practice. The New England Journal of Medicine 2003;348:2377-2378.

4. Villalba-Alcalá F, et al. Ambulatory blood pressure monitoring to study white coat effect in patients with hypertension followed in primary care. Revista Española de Cardiología 2004;57:652-650.

5. Augustovski FA, et al. The deep-breath test as a diagnostic maneuver for white-coat effect in hypertensive patients. J Amer B Family Pract 2004;17:184-189.

6. Nakashima T. White-coat hypertension contributes to the presence of carotid arteriosclerosis. hipertension Reserch 2004;27:10.

7. Owens P, et al. Monitoring diagnosis of white coat hypertension by ambulatory blood pressure. J Amer Heart Ass 1999;34:267-272.

8. Moser M, et al. Resitant or difficult to control hypertension. New England J Med 2006;355:385-392.

9. Curgunlu A, et al. Hyperhomocysteinemia an additional risk factor in white coat hypertension. Internal Heart Journal 2005;46:245-254.

10. Tseng YZ. Applications of 24-hour noninvasive ambulatory blood pressure monitoring. J Formos Med Assoc 2006;105(12).

11. Yamagishi T. Beneficial effect of cilnidipine on morning hypertension and white-coat effect in patients with essential hypertension. Hypertens Reserch 2006;29(5).

12. Owens P, et al. Monitoring diagnosis of white coat hypertension by ambulatory blood pressure. J Amer Heart Assoc 1999;34:267-272.

13. García-Río F. White coat hypertension in patients with syndrome obstructive sleep apnea-hypopnea. Chest 2004;125:817-822.

14. Verdecchia P, et al. Short- and long-term incidence of stroke in white-coat hypertension. J Amer Heart Assoc 2005;45:203-208.

15. Kaplan N. Measurement of blood pressure. In: Clinical Hypertension. Baltimore: William and Wilkins, 1994. 16. Alastair JJ. Obesity. New Engl J Med 2002;346:591-602.